H.R. 5371 § 781: The Redefinition of Hemp

This page is analysis and advocacy — it is not legal advice

Read this before you read anything else on the page. What follows is a research and policy brief. It is written to be used by regulators, legislators, counsel and industry researchers as an argument, and the argument is stated at full strength because a hedged brief is useless to the people who need it. It is not a legal opinion, it is not a clearance, and it is not advice to you. Three things make that more than a formality. First, cannabinoid law varies enormously by state: a compound that is lawful under federal law can be a felony in the jurisdiction where you live, ship, store or sell, and state analogue statutes, total-intoxicant caps and compound-by-name bans operate independently of the federal scheme described here. Second, this area of law is changing quickly — the federal definition of hemp itself was rewritten in late 2025 with a delayed effective date, state legislatures have moved in both directions in every recent session, and agency positions have shifted. Anything written here can be overtaken by an amendment, a rule, or a decision. Third, an argument that a substance is not a controlled substance analogue is a defence, not a permission: it is something a defendant says after being charged, and the fact that it is a good argument does not mean nobody will be charged. Do not make a business decision, a product decision or a personal decision on the basis of this page. Get your own lawyer, licensed in your own jurisdiction, and give them the actual facts. This page analyses a provision that is enacted but not yet effective, and whose implementing rules do not exist. Anything here can be overtaken by rulemaking, amendment or litigation before 12 November 2026.

• Not legal advice, and no lawyer-client relationship arises from reading it.
• Federal lawfulness does not imply state lawfulness — check your own state, and the states you ship to.
• The law described here is in motion; a delayed federal effective date sits in the middle of it.
• A strong non-analogue argument is a defence to a charge, not immunity from one.
• Nothing here is medical advice either, and nothing here is an endorsement of using any compound.

What the provision does

Section 781 of H.R. 5371 rewrites the federal definition of hemp. Four changes matter. First, the plant-level standard moves from delta-9 THC alone to total tetrahydrocannabinols, expressly including tetrahydrocannabinolic acid, so the decarboxylation arithmetic is built into the definition rather than left to enforcement practice. Second, a quantifiable threshold is imposed at the level of the finished article: a hemp-derived cannabinoid product for ingestion, inhalation or topical use must contain not more than 0.4 mg of total THC per container, with container defined as the innermost wrapping, packaging or vessel in direct contact with the product. Third, cannabinoids that are not naturally produced by the cannabis plant, or that are synthesised outside the plant, are excluded from the definition of hemp — which places them back under the Controlled Substances Act as tetrahydrocannabinols or as whatever else they are. Fourth, the standard extends beyond named compounds to other cannabinoids determined to have, or to be marketed as having, effects similar to THC, with that determination resting with the federal health authorities. The provision was enacted on 12 November 2025 with a one-year delayed effective date of 12 November 2026.

• Plant level: total tetrahydrocannabinols including THCA, at 0.3 percent dry weight.
• Product level: a hard quantity, 0.4 mg total THC per container.
• Definitional exclusion: not naturally produced by the plant, or synthesised outside it.
• Open-ended extension: other cannabinoids with similar, or similar-marketed, effects.
• One-year transition to 12 November 2026.

Sources: United States Congress 2025 · Congressional Research Service 2025 · Arnold & Porter 2025

Container, not serving — correcting a widespread error contested

The operator's source brief, and a great deal of trade commentary, states the threshold as 0.4 mg per serving. That is wrong, and the error matters enough to correct explicitly, because per container and per serving are different rules with very different consequences. Per serving, a manufacturer can comply by shrinking the serving and putting many servings in a package: a thirty-piece jar at 0.4 mg per piece is 12 mg in the jar. Per container, the whole package is the unit, and the only compliant thirty-piece jar is one containing 0.4 mg in total — about 13 micrograms per piece. The provision as reported is per container, and container is defined as the innermost wrapping, packaging or vessel in direct contact with the product, which is a deliberate anti-avoidance definition: it forecloses the argument that an individually wrapped piece inside a jar is its own container in the sense that matters, and it forecloses splitting a dose across a multi-pack. One caveat on the level of confidence. The per-container framing and the definition of container are taken here from the Congressional Research Service product and from law-firm analyses of the enacted text; the statutory text itself was not read line by line in this pass. Anyone relying on the distinction in a filing or a product decision should read section 781 as enacted.

Contested — caveat. FLAGGED. The per-container framing and the definition of container are taken from the CRS In Focus product and law-firm analyses of the enacted text, not from a line-by-line reading of section 781 itself. The correction of the operator's "per serving" claim is made with that qualification. Read the statute before relying on it.

Sources: United States Congress 2025 · Congressional Research Service 2025 · Arnold & Porter 2025

Why a milligram-per-container rule is a different regulatory object from a percentage by dry weight

This is the analytical core of the provision and it is routinely underestimated. A percentage by dry weight is a concentration limit on a commodity. It is dimensionless, it scales with the size of the article, and it says nothing about the quantity a person consumes: a large low-concentration article can contain a large absolute quantity of the analyte and still comply. That is precisely how the 2018 definition, applied to finished products, permitted 10 mg gummies — the cannabinoid was a small fraction of the mass of the confection. A milligram limit per container is an absolute quantity limit on a dose-bearing unit. It does not scale. It is indifferent to how large the article is or what else is in it. It is, in regulatory form, a pharmaceutical unit-dose limit rather than an agricultural commodity specification, and it is the form used to say "this product may not be intoxicating" rather than the form used to say "this crop is fibre hemp, not drug cannabis". The shift also relocates the point of measurement: a dry-weight percentage is measured on biomass at or near harvest, while a milligram-per-container standard is measured on the finished article, which means laboratory burden, chain of custody, batch homogeneity and label accuracy all move to the end of the supply chain. A product that is homogeneous on average and variable per unit can fail a per-container test while passing a percentage test on the same batch. That is a real compliance consequence and it is an argument for engaging with the provision at the level of analytical method, not only at the level of the number.

Sources: United States Congress 2025 · United States Code 2018 · Congressional Research Service 2025

Synthesised and converted cannabinoids contested

The exclusion of cannabinoids not naturally produced by the cannabis plant, or synthesised outside it, does two distinct things and they should not be run together. Its clear effect is to place beyond the definition of hemp the compounds that plainly do not occur in the plant: the acetate esters, the hydrogenated cannabinoids, and anything constructed on a non-cannabinoid scaffold. For those, the provision settles a question that the DEA interim final rule asserted and that the Fourth Circuit in Anderson declined to treat as settled. Its unclear effect concerns conversion. A cannabinoid that does occur in the plant, but which in a given article was obtained by chemically rearranging a different plant-derived cannabinoid, satisfies "naturally produced by the plant" as a statement about the molecule and fails it as a statement about the article's history. Which reading the provision takes is the whole question for the converted-cannabinoid market, and the phrase "or is synthesized outside of the plant" appears designed to resolve it against that market — but "synthesised" is doing heavy lifting for a single-step rearrangement of a plant-derived precursor, and the DEA's "synthetically derived" formulation has never received an authoritative construction either. It is worth saying plainly what the underlying chemical fact is, because the policy argument depends on it and nothing else here does: the acid-catalysed isomerisation of cannabidiol to the tetrahydrocannabinols is documented in the literature from Adams in 1940 and 1941, through Gaoni and Mechoulam in 1966, the Webster, Sarna and Mechoulam patent of 2008, the review by Bloemendal and colleagues in 2020, and the forensic examination by Kiselak and colleagues in 2020, and it is chemically undemanding. That is the fact a regulator needs in order to understand why the line between converted and natural material is hard to police. No procedure, reagent, condition or yield is stated on this shelf, and none is needed for the argument.

Contested — caveat. How section 781 treats single-step conversion of a plant-derived precursor to a cannabinoid that does occur in the plant is not resolved on the face of the reported text and will require rulemaking or litigation. The isomerisation literature is cited to establish that the chemistry is documented and undemanding, which is a policy proposition; no procedure is reproduced.

Sources: United States Congress 2025 · Drug Enforcement Administration 2020 · United States Court of Appeals for the Fourth Circuit 2024 · Adams R 1940 · Adams R 1941 · Gaoni Y 1966 · Webster GRB 2008 · Bloemendal VRLJ 2020 · Kiselak TD 2020

The "similar effects" designation authority contested

The provision does not depend on a closed list. It extends to cannabinoids determined to have, or to be marketed as having, effects on humans or animals similar to those of THC, with that determination resting with the federal health authorities. That is a structural answer to the enumeration problem: the reason compound-by-compound prohibition has failed in this field is that the combinatorial space of cannabinoid structures is large — eleven or so structural classes in the plant, several side-chain lengths, several ring closures and double-bond positions, and stereoisomers — and a list is always behind. A designation power keyed to effect rather than to identity does not have that defect. It has others. A power to designate by similarity of effect reproduces, in administrative form, the same undefined comparison that makes the Analogue Act vulnerable, and the "or is marketed as having" limb makes the legal status of a molecule depend on a seller's marketing copy rather than on the molecule. That is a live vagueness and delegation question, and it is the part of section 781 most likely to be litigated on its own terms rather than at the margins.

Contested — caveat. The scope and procedure of the designation authority, including whether it requires notice-and-comment rulemaking, were not confirmed in this pass and are among the details most likely to be clarified by implementing rules.

Sources: United States Congress 2025 · Congressional Research Service 2025 · United States Code 1986 · Radwan MM 2021 · ElSohly MA 2005

Comparison with the state standards already in force

The federal threshold is not a novel regulatory form. It is the form several states already use, set one to two orders of magnitude lower. Minnesota, which built a regulated hemp-edible market before its adult-use system, permits not more than 5 mg of any tetrahydrocannabinol per serving and not more than 50 mg per package for edibles, and not more than 10 mg per single beverage container. Adult-use cannabis programmes typically work in the same units, with per-serving limits around 5 to 10 mg and per-package limits in the tens to low hundreds of milligrams. Against that landscape, 0.4 mg per container is not a lower cap on a comparable regime; it is a different intent. A 10 mg beverage limit is a dose ceiling for an intoxicating product. A 0.4 mg per-container limit is below any dose at which delta-9 THC produces a reliable effect in a naive adult, and for a multi-serving package it is far below. That is a legitimate legislative choice — the provision is plainly meant to end the intoxicating hemp market rather than to cap it — but the analysis should name it as such. Calling it a potency limit understates it; it is a category prohibition expressed as a number, and the debate should be conducted on that basis.

Sources: United States Congress 2025 · Minnesota Statutes 2022 · United States Code 2018

What it reaches and what it does not

Taken as drafted, the provision reaches further than any previous federal instrument in this area, and the places it does not reach are worth identifying precisely rather than rhetorically. It reaches the whole intoxicating hemp-derived product market by quantity, irrespective of which cannabinoid is present, because total THC plus a designation power keyed to similar effects is close to comprehensive as to THC-type compounds. It reaches the converted-cannabinoid trade through the definitional exclusion, subject to the construction question above. It does not, by its terms, reach a cannabinoid that occurs in the plant, is not a tetrahydrocannabinol, is not designated as having similar effects, and is intoxicating by some other mechanism — that is a narrow gap but it is a real one, and it points at exactly the structural classes the research frontier is exploring. It does not reach the chemistry: the isomerisation and homologation literature is published, and a definition cannot unpublish it. It does not, on its own, reach conduct outside commerce in finished articles. And it leaves the whole of state law untouched, in both directions — a state may prohibit more, and a state with a licensed adult-use market will continue to permit far more inside it, so the practical effect of the provision is largely to push intoxicant demand toward state-licensed cannabis where that exists and toward unregulated supply where it does not. That last point is the subject of the market-consequences page.

Sources: United States Congress 2025 · United States Code 2018 · Radwan MM 2021 · Bloemendal VRLJ 2020 · Minnesota Statutes 2022

Uncertainty ledger for this page contested

Stated separately so it cannot be missed. The following details of the provision are taken from authoritative secondary sources — the Congressional Research Service product and law-firm analyses of the enacted text — rather than from a line-by-line reading of section 781 in this pass, and each should be checked against the statute before it is relied on.

• The internal subsection numbering of § 781 and the exact codified locations it amends.
• The precise statutory wording of the total-THC standard and of the 0.4 mg threshold.
• The definition of container as the innermost wrapping in direct contact with the product.
• Whether the threshold has any per-serving or per-dosage-unit component in addition to the per-container limit.
• The scope, procedure and reviewability of the similar-effects designation authority.
• Whether any category of product (topical, non-consumable, industrial) is carved out.
• Whether the 12 November 2026 date is a single effective date or a phased one.

Contested — caveat. Every item in this list is an acknowledged gap in verification, not a statement of law. The enactment date, the 12 November 2026 effective date, the per-container framing and the total-THC standard are corroborated across the CRS product and multiple independent law-firm analyses; the statutory text itself was not read in this pass.

Sources: United States Congress 2025 · Congressional Research Service 2025 · Arnold & Porter 2025